FDA Approval Boosts DRI Healthcare’s Investment in Ekterly

An update from DRI Healthcare ( ($TSE:DHT.UN) ) is now available.

DRI Healthcare announced the FDA approval of Ekterly, developed by KalVista Pharmaceuticals, as the first and only oral on-demand therapy for hereditary angioedema (HAE), a rare genetic disorder. This approval enhances DRI Healthcare’s portfolio value, as they are entitled to tiered royalties on Ekterly’s global sales, with potential milestone payments, following KalVista’s decision to increase funding, bringing DRI’s total investment to $127 million.

The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.

Spark’s Take on TSE:DHT.UN Stock

According to Spark, TipRanks’ AI Analyst, TSE:DHT.UN is a Neutral.

DRI Healthcare Trust’s strong balance sheet and effective cash flow management are overshadowed by profitability challenges due to revenue decline and net losses. Technical analysis shows a bearish trend, and valuation concerns arise from negative earnings. However, recent corporate events indicate a positive outlook with improved financial results and strategic management, providing a moderate boost to the overall score.

To see Spark’s full report on TSE:DHT.UN stock, click here.

More about DRI Healthcare

DRI Healthcare is a leader in the global pharmaceutical royalty monetization industry. Since its inception in 1989, the company has invested over $3.0 billion in acquiring more than 75 royalties on over 45 drugs, including notable names like Ekterly, Eylea, and Keytruda. DRI Healthcare’s units are traded on the Toronto Stock Exchange under the symbols DHT.UN and DHT.U.

Average Trading Volume: 51,351

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$773.2M

For an in-depth examination of DHT.UN stock, go to TipRanks’ Overview page.